Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...

Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...

(UroToday.com) The 2022 American Urological Association Annual Meeting included a prostate cancer session featuring work from Dr. Mohammad Siddiqui and colleagues presenting results of their study ...

ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.

(UroToday.com) The 2023 European Society of Medical Oncology (ESMO) Annual Congress held in Madrid, Spain between October 20 th and 24 th, 2023 was host to a non-prostate genitourinary proffered paper ...

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Andrew Armstrong presented the final overall survival ...

(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...

(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th ...

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...

(UroToday.com) The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Zachery R. Reichert and colleagues presenting results of the TRAP trial, targeting ...